Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

A self-healing radiopaque hyaluronic acid hydrogel as a new injectable biomaterial for precision medicine in osteoarthritis

Said M., Tavakoli C., Dumot C., Toupet K., Olivier C., Gilles A.

Animal Study on Knee Osteoarthritis, Osteoarthritis, published in Theranostics (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Theranostics (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40213675
PMCID
PMC11980665
DOI
10.7150/thno.104551
Citations
1

Abstract (original English)

Rationale: Osteoarthritis (OA) is a degenerative disease affecting cartilage, synovium and bone, that is a major cause of pain and disability. Intra-articular injection of hyaluronic acid (HA) derivatives, also known as viscosupplementation (VS), is a common treatment for the symptomatic management of knee OA. Despite its widespread use, the magnitude of the clinical benefit of VS remains controversial, with conflicting results due to methodological differences and possible differences in efficacy between products related to remanence and rheological properties. Methods: Here, to create an effective HA-based treatment, an injectable self-healing HA hydrogel with long-persistent radiopacity is formed by tethering a clinical iodine contrast agent to HA. The labeling conditions are tuned to obtain sufficient X-ray signal without altering the biocompatibility, rheological and injectability properties of the hydrogel. Results: The iodine labeling enabled to monitor not only delivery of the hydrogel but also its retention in mouse knees up to 5 weeks post-administration using synchrotron K-edge subtraction-computed tomography. We further demonstrated that the unique properties of this hydrogel enable creation of a transient HA network in vivo that attenuates OA progression in a mouse model of OA. Moreover, our data showed that the rate of HA-I disappearance appears to predict treatme

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsHumansMiceOsteoarthritisOsteoarthritis, KneeDisease Models, AnimalHyaluronic AcidBiocompatible MaterialsHydrogelsContrast Media

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research